Navigation Links
Sunesis Reports Financial Results for the Second Quarter 2009
Date:7/29/2009

other applicable criteria for continued listing on The NASDAQ Capital Market, but for the $1.00 bid price requirement, which has been suspended by NASDAQ through August 2, 2009. If the application is approved, the company will no longer be subject to delisting from NASDAQ as a result of the previously disclosed stockholders' equity deficiency as of December 31, 2008, but it will need to comply with The NASDAQ Capital Markets' continued listing requirements on an ongoing basis.

Financial Highlights

  • Revenues for the three and six months ended June 30, 2009 were $3.5 million and $3.7 million compared to $2.6 million and $4.9 million for the same periods in 2008. Sunesis recognized $2.0 million in the second quarter of 2009 for the sale to SARcode of its interest in the lymphocyte function-associated antigen-1, or LFA-1, patents and related know-how that had previously been the subject of a license agreement with them, and $1.5 million for the Biogen Idec Raf kinase inhibitor milestone referred to above. Revenues in the 2008 periods were primarily related to research funding under the Biogen Idec collaboration.
  • Research and development expenses decreased to $3.4 million and $7.7 million for the three and six months ended June 30, 2009 from $8.3 million and $17.0 million for the same periods in 2008. The decreases were primarily due to savings from the termination of substantially all discovery research activities in June 2008.
  • General and administrative expenses for the first three and six months of 2009 were $2.0 million and $4.3 million compared to $3.2 million and $6.5 million for the same periods in 2008. The decreases were primarily due to reduced administrative headcount and facility costs as a result of the company's June 2008 and March 2009 restructurings.
  • Restructuring charges of $1.9 million were recorded in the first half o
    '/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
2. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
4. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
5. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
6. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
7. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
10. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
11. Sunesis to Present at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... SAN FRANCISCO , July 29, 2015 /PRNewswire/ ... trialling mobile molecular testing for applications in food ... Ubiquitome,s hand-held, battery powered real-time PCR device, the ... the farm right through to the supermarket shelf ... world. This includes involvement in animal disease control ...
(Date:7/29/2015)... ... July 29, 2015 , ... Brady (NYSE:BRC), a global leader ... . To align chemical container labeling with OSHA’s updated Hazard Communication (HazCom) Standard ... an example of an accurate label, and pictogram uses and meanings. , “With ...
(Date:7/29/2015)... -- Pfenex Inc. (NYSE MKT: PFNX) announced today that its ... Thursday, August 13, 2015, before the open of market.  ... a conference call to discuss the financial results and ... financial results and business update will be publicly distributed ... (US) or 1-412-542-4131 (international) and reference Pfenex to access ...
(Date:7/29/2015)... VANCOUVER , July 29, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company, is pleased to announce ... dermal injector (RCI-02) have been locked.  Prototypes for ... to prepare for an application for CE mark ... Europe in 2016. (Photo: ...
Breaking Biology Technology:AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2Brady Announces a New GHS Label Guide 2Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5
... supports need for new way of thinking in integrated imaging , ... First introduced at the European Society of Nuclear Medicine ... running, experiencing high demand in a time when the current economical ... mCT reaches the United States as a pioneer, not ...
... Fla., Dec. 1 Imaging Diagnostic,Systems, Inc., (OTC Bulletin ... today that a recent study on CTLM is one ... - December 5th. Dr. Jin Qi,a radiologist at ... was selected for her paper, "CTLM as an Adjunct ...
... Dec. 1 The Female Health Company,(Amex: FHC ... record operating results for the quarter and fiscal year ended,September ... the three months ended September 30, 2008, net revenues increased ... ended September 30,2007. The Company reported net income attributable to ...
Cached Biology Technology:Imaging in Living Color with Siemens Molecular CT 2Imaging in Living Color with Siemens Molecular CT 3Imaging in Living Color with Siemens Molecular CT 4Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference 2Imaging Diagnostic Systems CT Laser Mammography (CTLM(R)) System Featured at the 94th Annual Radiological Society of North America (RSNA) Conference 3The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance 2The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance 3The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance 4The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance 5The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance 6The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance 7The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance 8
(Date:6/24/2015)... JOSE, Calif. , June 24, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that ... sensor to provide secure authentication for its latest ... recently reached more than 200 million shipments of ... with Sharp reinforces Synaptics, strength, scalability and leadership ...
(Date:6/24/2015)... June 24, 2015 Biometry authentication provider ... biometric password solution one face in. ... one face in, entering the expanding biometric ... affordable multifactor-authentication biometric answer to the password problem. ... in partnership with KeyLemon, one face in allows ...
(Date:6/23/2015)... Research and Markets( ... "Body-Worn Temperature Sensors Market - Global Industry ... - 2020" report to their offering. ... global body-worn temperature sensors market. The global body-worn ... basis of types, care setting, patient demographic, applications ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... release is also available in Chinese on ... research released today by the Rights and Resources Initiative (RRI) ... women continue to be largely marginalized and ignored or exploited ... of global climate and poverty reduction goals. This ...
... in thousands of small divots. Hit these cells with drugs ... a cancer drug. But a review published this week in ... that these 2D models in fact offer very little information ... often give researchers misleading results. "Up until the ...
... its 46th Congress, the International Society for Applied Ethology (ISAE) ... at the University of Veterinary Medicine, Vienna (Vetmeduni Vienna) from ... opinions on the latest developments regarding the behaviour and well-being ... year is the quality of life of animals in man-made ...
Cached Biology News:Research warns Asia unlikely to achieve climate, poverty goals unless women's rights are recognized 2Research warns Asia unlikely to achieve climate, poverty goals unless women's rights are recognized 3Research warns Asia unlikely to achieve climate, poverty goals unless women's rights are recognized 4Research warns Asia unlikely to achieve climate, poverty goals unless women's rights are recognized 5Research warns Asia unlikely to achieve climate, poverty goals unless women's rights are recognized 63-D tumor models improve drug discovery success rate 23-D tumor models improve drug discovery success rate 3International congress on behavior, animal husbandry and animal well-being in Vienna 2
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
... The SilverQuest Silver Staining Kit ... silver staining sensitivity with minimal protein ... The mass spectrometry problems associated with ... the SilverQuest kit because the reagents ...
...
Biology Products: